JAMES KLINE: Open Payments
NPI 1811960347 · WYOMISSING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,870 in 163 payments from 23 companies in 2025. Trend: 2023 $2,439 · 2024 $5,613 · 2025 $10,870
Speaker / faculty: $5,535Food & beverage: $3,389Consulting: $1,080Travel & lodging: $768Education: $99
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 25 | $7,480 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $684 |
| ABBVIE INC. | 39 | $478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $319 |
| Janssen Biotech, Inc. | 10 | $303 |
| PFIZER INC. | 15 | $274 |
| Ardelyx, Inc. | 7 | $262 |
| GENZYME CORPORATION | 7 | $170 |
| Gilead Sciences, Inc. | 3 | $169 |
| Regeneron Healthcare Solutions, Inc. | 7 | $139 |
Products named: REZDIFFRA, XIFAXAN, DUPIXENT, TREMFYA, IBSRELA, ENTYVIO, VELSIPITY, CREON.
Industry payments across PA — which companies pay providers there.
